<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03532971</url>
  </required_header>
  <id_info>
    <org_study_id>17-664</org_study_id>
    <nct_id>NCT03532971</nct_id>
  </id_info>
  <brief_title>Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes</brief_title>
  <official_title>Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is evaluating the reactivation of BK virus in patients who have undergone
      allogeneic hematopoietic-cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Every year, more than 25,000 patients worldwide receive lifesaving bone marrow
      transplantations with hematopoietic-cells from another person. It is estimated that over 75%
      of these patients will develop an infectious complication, of which approximately one third
      can be life-threatening. A significant proportion of these infections are caused by
      opportunistic viruses, such as BK virus.

      This virus establishes latent infection in most individuals, but does not normally cause
      disease. It can reactivate after hematopoietic-cell transplantation and represents the second
      most common viral infection in this patient population. BK virus is associated with kidney
      failure and a decreased chance of survival after hematopoietic-cell transplantation. There
      are no effective antiviral treatments for this disease.

      Despite being the second most common cause of clinical disease hematopoietic-cell
      transplantation, very little is known about this virus. To address this knowledge gap, the
      investigators aim to study patients with confirmed BK virus disease post allogeneic
      hematopoietic-cell transplantation.

      As part of this study, regular urine and blood tests will be done to understand how the virus
      behaves over time and which organs it affects. Blood and urine samples will also be obtained
      to study how the immune system rebuilds itself after hematopoietic-cell transplantation.
      Finally, an ultrasound of the kidneys and the bladder will be done to evaluate for any
      presence of disease in these organs.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 11, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The mean total number of cytokine producing BKV-specific NK and T-cells at the time of BKVD in affected patients, as compared with unaffected patients</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analytically determine a BKV-specific cfDNA methylation pattern in the urine and plasma samples of affected patients</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analytically determine BKV-specific antibody glycosylation patterns in plasma samples of patients who exhibit BKVR.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">125</enrollment>
  <condition>BK Virus Infection</condition>
  <arm_group>
    <arm_group_label>allogeneic hematopoietic-cell transplantation patients</arm_group_label>
    <description>Prospective HCT cohort of patients undergoing allogeneic HCT at DFCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Symptom index questionnaire</intervention_name>
    <description>A survey administered to identify the symptoms of the patient</description>
    <arm_group_label>allogeneic hematopoietic-cell transplantation patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>BK polyomavirus PCR</intervention_name>
    <description>quantitative PCR testing</description>
    <arm_group_label>allogeneic hematopoietic-cell transplantation patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>quality of life questionnaires</intervention_name>
    <description>Standard questionnaires validated for HCT recipients</description>
    <arm_group_label>allogeneic hematopoietic-cell transplantation patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients who undergo allo-HCT will be eligible for the study, regardless of age,
        underlying disease, conditioning regimen, or GVHD prophylaxis regimen
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult ≥18 years old

          -  All adult patients who undergo allo-HCT will be eligible for the study, regardless of
             age, underlying disease, conditioning regimen, or GVHD prophylaxis regimen

        Exclusion Criteria:

          -  Adults unable to consent

          -  Individuals who are not yet adults (infants, children, teenagers)

          -  Pregnant women

          -  Prisoners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Francisco Marty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francisco M. Marty, MD</last_name>
    <phone>617-525-8418</phone>
    <email>fmarty@bwh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthew P. Cheng, MD</last_name>
    <phone>617-525-8418</phone>
    <email>mcheng@bwh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francisco M. Marty, MD</last_name>
      <phone>617-525-8418</phone>
      <email>fmarty@bwh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Matthew P. Cheng, MD</last_name>
      <phone>617-525-8418</phone>
      <email>mcheng@bwh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Francisco M. Marty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew P. Cheng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José L. Orejas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kaiwen Cheng</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2018</study_first_submitted>
  <study_first_submitted_qc>May 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2018</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Francisco M. Marty, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>BK virus</keyword>
  <keyword>BK polyomavirus</keyword>
  <keyword>hematopoietic-cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

